drugset / Trial / NCT03483259
To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a single-center, randomized, open, single-dose, three-cycle cross-design study, which will be only enrolled Chinese male healthy volunteers.
Timeline
- Start
- 2018-04-02
- Primary completion
- 2018-05-12
- Completion
- 2018-05-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 300 mg | Oral |
Indications
No indication recorded.